Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200
Status:
Not yet recruiting
Trial end date:
2023-12-20
Target enrollment:
Participant gender:
Summary
This Phase 2 study will evaluate the safety and efficacy of monthly intravenous doses of
IXT-m200 in treatment-seeking individuals with methamphetamine (METH) use disorder. The
hypothesis is that treatment with IXT-m200 will reduce the occurrence of stimulant-positive
samples compared to placebo (following an initial grace period during which relapses may
occur).